Cancer proteomic studies might identify disease-related biomarkers for early cancer diagnosis and new surrogate biomarkers for therapy efficacy, but also for guidance of optimal anticancer drug combinations, enabling tailor-made therapy.
Multiple technologies that measure expression levels of proteins in human samples offer a potential strategy for the detection and understanding of tumor formation.
A major goal of the cancer biomarker field is to develop non-invasive tests that allow the detection of cancer at its earliest stages.
Tumors are a heterogeneous group of neoplasms that appear to underlie individual patterns of growth, invasion, response to therapy and prognosis.
Cancer is the most commune diseases, with poor prognosis and low survival rate
Serum proteomic pattern diagnostics can offer specific signatures that can be used as a diagnostic classifier.
The interest for proteomics increased lately because this approach has recently shown great promise in the detection of early-stage cancers.
The array of serum markers comprises angiogenesis-related proteins, growth factors, cytokines, and enzymes and so on.
Although challenging, proteomic profiling has recently become one of the most important areas in cancer research, and the majority of the currently available methodologies, such as xMAP technology and SELDI-TOF-MS, was used in human tumor research. This technology may provide a panel of serum markers for early identification and monitoring disease progression.
Biomarker discovery for tumors is still continuing and the search for the best molecule or combination of serum compounds is even more up-to-date